News|Articles|May 7, 2024
Mobile Visits in Decentralized Clinical Trials: The Past, Present and Future
Author(s)PCM Trials
In March 2024, the US FDA issued its guidance, “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,” outlining the agency’s objectives for protecting public health as artificial intelligence (AI) and other technologies become more prevalent in healthcare.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Content
Trending on Applied Clinical Trials Online
1
SCOPE Summit 2026 Panel Discussion: Diversity in Clinical Trials—What’s Working, What’s Next
2
SCOPE Summit 2026 Keynote Panel: Is Radical Acceleration in Clinical Research Possible?
3
SCOPE Summit 2026: Reducing Patient Burden Is the Foundation of Wearable Success in Oncology
4
SCOPE Summit 2026: Elevating Patient Experience in Clinical Operations
5